Logo image of PDEX

PRO-DEX INC (PDEX) Stock Fundamental Analysis

NASDAQ:PDEX - Nasdaq - US74265M2052 - Common Stock - Currency: USD

47.82  +2.77 (+6.15%)

Fundamental Rating

6

PDEX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. PDEX has only an average score on both its financial health and profitability. PDEX is not overvalued while it is showing excellent growth. This is an interesting combination. This makes PDEX very considerable for growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year PDEX was profitable.
In the past year PDEX has reported a negative cash flow from operations.
In the past 5 years PDEX has always been profitable.
The reported operating cash flow has been mixed in the past 5 years: PDEX reported negative operating cash flow in multiple years.
PDEX Yearly Net Income VS EBIT VS OCF VS FCFPDEX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

1.2 Ratios

PDEX's Return On Assets of 14.58% is amongst the best of the industry. PDEX outperforms 96.26% of its industry peers.
Looking at the Return On Equity, with a value of 26.55%, PDEX belongs to the top of the industry, outperforming 96.26% of the companies in the same industry.
With an excellent Return On Invested Capital value of 19.83%, PDEX belongs to the best of the industry, outperforming 98.93% of the companies in the same industry.
PDEX had an Average Return On Invested Capital over the past 3 years of 11.81%. This is above the industry average of 7.89%.
The last Return On Invested Capital (19.83%) for PDEX is above the 3 year average (11.81%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 14.58%
ROE 26.55%
ROIC 19.83%
ROA(3y)9%
ROA(5y)12.39%
ROE(3y)15.75%
ROE(5y)22.01%
ROIC(3y)11.81%
ROIC(5y)13.41%
PDEX Yearly ROA, ROE, ROICPDEX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

PDEX has a better Profit Margin (14.61%) than 92.51% of its industry peers.
In the last couple of years the Profit Margin of PDEX has declined.
The Operating Margin of PDEX (18.24%) is better than 90.91% of its industry peers.
In the last couple of years the Operating Margin of PDEX has declined.
PDEX has a Gross Margin of 31.36%. This is in the lower half of the industry: PDEX underperforms 74.33% of its industry peers.
PDEX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 18.24%
PM (TTM) 14.61%
GM 31.36%
OM growth 3Y3.8%
OM growth 5Y-6.22%
PM growth 3Y-37.56%
PM growth 5Y-23.7%
GM growth 3Y-8.87%
GM growth 5Y-5.57%
PDEX Yearly Profit, Operating, Gross MarginsPDEX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

More info and screens

6

2. Health

2.1 Basic Checks

PDEX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for PDEX has been reduced compared to 1 year ago.
Compared to 5 years ago, PDEX has less shares outstanding
Compared to 1 year ago, PDEX has an improved debt to assets ratio.
PDEX Yearly Shares OutstandingPDEX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
PDEX Yearly Total Debt VS Total AssetsPDEX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

PDEX has an Altman-Z score of 6.17. This indicates that PDEX is financially healthy and has little risk of bankruptcy at the moment.
PDEX has a better Altman-Z score (6.17) than 81.28% of its industry peers.
A Debt/Equity ratio of 0.28 indicates that PDEX is not too dependend on debt financing.
PDEX has a Debt to Equity ratio of 0.28. This is comparable to the rest of the industry: PDEX outperforms 49.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Altman-Z 6.17
ROIC/WACC2.31
WACC8.59%
PDEX Yearly LT Debt VS Equity VS FCFPDEX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

PDEX has a Current Ratio of 2.73. This indicates that PDEX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.73, PDEX is in line with its industry, outperforming 53.48% of the companies in the same industry.
A Quick Ratio of 1.45 indicates that PDEX should not have too much problems paying its short term obligations.
The Quick ratio of PDEX (1.45) is worse than 60.96% of its industry peers.
Industry RankSector Rank
Current Ratio 2.73
Quick Ratio 1.45
PDEX Yearly Current Assets VS Current LiabilitesPDEX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 355.17% over the past year.
PDEX shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -6.76% yearly.
The Revenue has grown by 29.65% in the past year. This is a very strong growth!
Measured over the past years, PDEX shows a quite strong growth in Revenue. The Revenue has been growing by 14.66% on average per year.
EPS 1Y (TTM)355.17%
EPS 3Y-17.89%
EPS 5Y-6.76%
EPS Q2Q%331.58%
Revenue 1Y (TTM)29.65%
Revenue growth 3Y12.29%
Revenue growth 5Y14.66%
Sales Q2Q%21.84%

3.2 Future

PDEX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 97.88% yearly.
PDEX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.04% yearly.
EPS Next Y278.39%
EPS Next 2Y97.88%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year35.63%
Revenue Next 2Y19.04%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PDEX Yearly Revenue VS EstimatesPDEX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M
PDEX Yearly EPS VS EstimatesPDEX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

PDEX is valuated rather expensively with a Price/Earnings ratio of 18.11.
Compared to the rest of the industry, the Price/Earnings ratio of PDEX indicates a rather cheap valuation: PDEX is cheaper than 82.35% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.45, PDEX is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 19.70, the valuation of PDEX can be described as rather expensive.
79.14% of the companies in the same industry are more expensive than PDEX, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.90, PDEX is valued at the same level.
Industry RankSector Rank
PE 18.11
Fwd PE 19.7
PDEX Price Earnings VS Forward Price EarningsPDEX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PDEX is valued cheaper than 87.70% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 12.29
PDEX Per share dataPDEX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PDEX has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as PDEX's earnings are expected to grow with 97.88% in the coming years.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y97.88%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

PDEX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRO-DEX INC

NASDAQ:PDEX (7/3/2025, 7:59:33 PM)

47.82

+2.77 (+6.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)09-03 2025-09-03/amc
Inst Owners30.04%
Inst Owner Change-64.6%
Ins Owners35.95%
Ins Owner Change0%
Market Cap155.89M
Analysts82.86
Price Target57.12 (19.45%)
Short Float %7.86%
Short Ratio2.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)64.21%
Min EPS beat(2)57.38%
Max EPS beat(2)71.05%
EPS beat(4)4
Avg EPS beat(4)77.71%
Min EPS beat(4)28.85%
Max EPS beat(4)153.55%
EPS beat(8)5
Avg EPS beat(8)9.49%
EPS beat(12)7
Avg EPS beat(12)15.5%
EPS beat(16)7
Avg EPS beat(16)5.1%
Revenue beat(2)1
Avg Revenue beat(2)7.88%
Min Revenue beat(2)-3.54%
Max Revenue beat(2)19.3%
Revenue beat(4)3
Avg Revenue beat(4)18.85%
Min Revenue beat(4)-3.54%
Max Revenue beat(4)38.97%
Revenue beat(8)6
Avg Revenue beat(8)10.51%
Revenue beat(12)10
Avg Revenue beat(12)13.77%
Revenue beat(16)12
Avg Revenue beat(16)10.76%
PT rev (1m)3.7%
PT rev (3m)3.7%
EPS NQ rev (1m)-2.08%
EPS NQ rev (3m)-2.08%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.24%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.33%
Valuation
Industry RankSector Rank
PE 18.11
Fwd PE 19.7
P/S 2.43
P/FCF N/A
P/OCF N/A
P/B 4.42
P/tB 4.42
EV/EBITDA 12.29
EPS(TTM)2.64
EY5.52%
EPS(NY)2.43
Fwd EY5.08%
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS19.67
BVpS10.82
TBVpS10.81
PEG (NY)0.07
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 14.58%
ROE 26.55%
ROCE 25.45%
ROIC 19.83%
ROICexc 25.27%
ROICexgc 25.29%
OM 18.24%
PM (TTM) 14.61%
GM 31.36%
FCFM N/A
ROA(3y)9%
ROA(5y)12.39%
ROE(3y)15.75%
ROE(5y)22.01%
ROIC(3y)11.81%
ROIC(5y)13.41%
ROICexc(3y)13.33%
ROICexc(5y)16.93%
ROICexgc(3y)13.36%
ROICexgc(5y)17.03%
ROCE(3y)15.15%
ROCE(5y)17.2%
ROICexcg growth 3Y11.8%
ROICexcg growth 5Y-12.49%
ROICexc growth 3Y11.98%
ROICexc growth 5Y-12.32%
OM growth 3Y3.8%
OM growth 5Y-6.22%
PM growth 3Y-37.56%
PM growth 5Y-23.7%
GM growth 3Y-8.87%
GM growth 5Y-5.57%
F-Score6
Asset Turnover1
Health
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Debt/EBITDA 0.76
Cap/Depr 102.36%
Cap/Sales 1.96%
Interest Coverage 16.27
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.73
Quick Ratio 1.45
Altman-Z 6.17
F-Score6
WACC8.59%
ROIC/WACC2.31
Cap/Depr(3y)140.73%
Cap/Depr(5y)342.39%
Cap/Sales(3y)2.61%
Cap/Sales(5y)6.21%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)355.17%
EPS 3Y-17.89%
EPS 5Y-6.76%
EPS Q2Q%331.58%
EPS Next Y278.39%
EPS Next 2Y97.88%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)29.65%
Revenue growth 3Y12.29%
Revenue growth 5Y14.66%
Sales Q2Q%21.84%
Revenue Next Year35.63%
Revenue Next 2Y19.04%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y81.9%
EBIT growth 3Y16.56%
EBIT growth 5Y7.53%
EBIT Next Year80%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-7.3%
FCF growth 3YN/A
FCF growth 5Y22%
OCF growth 1Y-11.14%
OCF growth 3YN/A
OCF growth 5Y13.23%